

ForPatients

by Roche

Autism Spectrum Disorder

Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03507569 BP40257

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773 in healthy participants.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03507569 BP40257
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 23 Years & <= 55 Years

Healthy Volunteers
Accepts Healthy Volunteers
